{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:47:09Z","timestamp":1790192829061,"version":"4.1.0"},"reference-count":49,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T00:00:00Z","timestamp":1532649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2018,9]]},"abstract":"Abstract<\/jats:title>Objective<\/jats:title>To evaluate response rates and survival in adults with transplant\u2010associated thrombotic microangiopathy (TA<\/jats:styled-content>\u2010TMA<\/jats:styled-content>) after allogeneic hematopoietic stem cell transplantation (HSCT<\/jats:styled-content>) who were treated with eculizumab (ECU<\/jats:styled-content>).<\/jats:p><\/jats:sec>Methods<\/jats:title>Patients were identified retrospectively and data collected through HSCT<\/jats:styled-content> and pharmacy databases.<\/jats:p><\/jats:sec>Results<\/jats:title>Ten patients with TA<\/jats:styled-content>\u2010TMA<\/jats:styled-content> after allogeneic HSCT<\/jats:styled-content> were treated with ECU<\/jats:styled-content> between 2013 and 2016. TA<\/jats:styled-content>\u2010TMA<\/jats:styled-content> was diagnosed at a median of 93\u00a0days post\u2010HSCT<\/jats:styled-content>. Organ\u2010specific injury was documented in all ten patients at time of TA<\/jats:styled-content>\u2010TMA<\/jats:styled-content> diagnosis, the most common being renal dysfunction (90%). Acute GVHD<\/jats:styled-content> (70%) and active infection (80%) were common at time of diagnosis. The median time to ECU<\/jats:styled-content> initiation from TA<\/jats:styled-content>\u2010TMA<\/jats:styled-content> diagnosis was 4\u00a0days. Seven patients received ECU<\/jats:styled-content> as first\u2010line therapy in combination with other treatment modalities, while three patients were treated with ECU<\/jats:styled-content> as second\u2010line therapy. ECU<\/jats:styled-content> was well tolerated with the exception of one case of severe skin rash leading to discontinuation. ECU<\/jats:styled-content> achieved an overall hematologic response rate of 70% and an overall survival rate of 60%. One patient achieved a complete response with corresponding organ recovery.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Early initiation of ECU<\/jats:styled-content> may not alter the disease process enough to restore organ function, but it may prolong survival.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13127","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T17:45:09Z","timestamp":1529430309000},"page":"389-398","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Eculizumab for transplant\u2010associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients"],"prefix":"10.1111","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7143-4063","authenticated-orcid":false,"given":"Joslyn","family":"Rudoni","sequence":"first","affiliation":[{"name":"Department of Pharmacy Cleveland Clinic Health System Cleveland Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jan","sequence":"additional","affiliation":[{"name":"Division of Pharmacy The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Hosing","sequence":"additional","affiliation":[{"name":"Division of Stem Cell Transplantation The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur","family":"Aung","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7422-8951","authenticated-orcid":false,"given":"Jason","family":"Yeh","sequence":"additional","affiliation":[{"name":"Division of Pharmacy The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,7,27]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.10.002"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.87"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1312353"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.61"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S102235"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.06.001"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2004.00700.x"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2010.033"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10699"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181f24e8d"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.10.006"},{"issue":"3","key":"e_1_2_5_13_1","first-page":"152","article-title":"Transplant\u2010Associated Thrombotic Microangiopathy (TA\u2010TMA) and consensus based diagnostic and therapeutic recommendations: which TA\u2010TMA patients to treat and when?","volume":"2","author":"Uderzo CCJS","year":"2014","journal-title":"J Bone Marrow Res"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2016.04.007"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705160"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.09.004"},{"issue":"9","key":"e_1_2_5_17_1","first-page":"565","article-title":"Hematopoietic transplant\u2010associated thrombotic microangiopathy: case report and review of diagnosis and treatments","volume":"12","author":"Chapin J","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705758"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703710"},{"issue":"4","key":"e_1_2_5_20_1","first-page":"495","article-title":"Thrombotic microangiopathy following bone marrow transplantation","volume":"14","author":"Pettitt AR","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/1076029615598221"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-564997"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705976"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.04.007"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200969020-00004"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2014.11.001"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1992.32893032096.x"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108083250604"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12859"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2007.03.004"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000601"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.233"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00687.x"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21470_c"},{"key":"e_1_2_5_35_1","unstructured":"Soliris (eculizumab)[package insert]. Alexion Pharmaceuticals Inc. Cheshire CT; March 2007 (Available at:http:\/\/soliris.net\/resources\/pdf\/soliris_pi.pdf). In."},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501445"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.12.565"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12202"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.97"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/1076029615599439"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.4081\/hr.2015.6107"},{"key":"e_1_2_5_42_1","first-page":"425410","article-title":"Renal and neurological response with eculizumab in a patient with transplant associated thrombotic microangiopathy after allogeneic hematopoietic progenitor cell transplantation","volume":"2015","author":"Sevindik OG","year":"2015","journal-title":"Case Rep Hematol"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.08.019"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.03.032"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.01.434"},{"key":"e_1_2_5_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.253"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21265"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761346"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12996"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.07.004"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13127","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13127","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T16:04:12Z","timestamp":1694966652000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,27]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1111\/ejh.13127"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13127","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,27]]},"assertion":[{"value":"2018-06-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}